At Variant, we are developing breakthrough treatments to tackle unmet medical needs in rare genetic vision disorders.
Single Treatment Tackles Multiple Diseases
Regardless of the mutation, gene, or disease mechanism, VAR-002 can target multiple diseases, cutting costs, shortening development timelines, and more effectively addressing the genetic diversity of rare disorders.
Restores Vision & Halts Progression
It reinforces partially active mutated genes, restoring significant visual function and slowing disease progression.
Targets the CRX Transcription Factor, Not An Individual Gene
VAR-002 expresses the CRX transcription factor, which is essential for healthy photoreceptors (cones and rods). This approach enables treatment across a wide range of retinal dystrophies.
Widespread Neuroprotection
It offers global neuroprotection, promoting photoreceptor survival and slowing degeneration.